UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 11)

Enzo Biochem, Inc.
(Name of Issuer)
Common Stock, \$.01 par value
(Title of Class of Securities)
294100102
(CUSIP Number)
December 31, 2011
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

× Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5 pages

IN

	Enzo Biochem, Inc.
(b)	Address of Issuer's Principal Executive Offices 60 Executive Blvd Farmingdale, NY 11735
(a)	Name of Person Filing Rosalind Davidowitz
(b)	Address of Principal Business Office or, if none, Residence Mrs. Davidowitz's address is 7 Sutton Place South, Lawrence, New York 11559.
(c)	Citizenship Mrs. Davidowitz is a United States citizen.
(d)	Title of Class of Securities Common Stock, \$.01 par value
(e)	CUSIP Number 294100102
If this	statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) (b) (c) (d) (e) (f) (g) (h) (i)	 □ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). □ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). □ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). □ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). □ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); □ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); □ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); £ A church plan that is excluded from the definition of an investment company under section 3(c) (14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); □ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
	(a) (b) (c) (d) (e) If this (a) (b) (c) (d) (e) (f) (g) (h) (i)

Item 1.

(a) Name of Issuer

Item 4. Ownership

- (a)(b) Amount beneficially owned (1):
 - As of December 31, 2011, Mrs. Davidowitz may be deemed to beneficially own 3,665,118 shares or 9.5% of the Issuer's shares issued and outstanding as follows (i) 1,938,738 shares owned directly by Rosalind Davidowitz, (ii) 381,713 shares owned directly by Mr. J. Morton Davis, Mrs. Davidowitz's husband (2), (iii) 1,207,196 shares owned by Engex, Inc. (3), (iv) 12,733 shares owned by an investment advisor whose principal is Mr. Davis, and (v) 124,738 shares owned by The Morton Foundation (4).
 - (c) Mrs. Davidowitz has sole power to dispose or to direct the disposition of those shares owned directly by her. Mr. Davis has sole power to vote or to direct the vote, to dispose or to direct the disposition of those shares owned by him and by the investment advisor. Voting and dispositive decisions regarding shares owned by Engex are made by Mr. Davis as Chairman of the Board.
- Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box . Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

- (1) Not included herein are shares owned by Kinder Investments, L.P. ("Kinder"), shares owned by Venturetek, L.P. ("Venturetek") and shares owned by Sutton Partners, L.P. ("Sutton"). The limited partners of Kinder, Venturetek, and Sutton are the children and grandchildren of Mrs. Davidowitz. Mrs. Davidowitz disclaims for purposes of Section 13 or otherwise beneficial ownership of any Enzo Biochem, Inc. shares owned by Kinder, Venturetek and Sutton. Kinder, Venturetek and Sutton disclaim for purposes of Section 13 or otherwise ownership of any Enzo Biochem, Inc. shares owned by Mrs. Davidowitz.
- (2) Filing of this statement shall not be deemed an admission by Rosalind Davidowitz that she beneficially owns the securities attributed to Mr. Davis for any purpose. Mrs. Davidowitz expressly disclaims beneficial ownership of all securities held by Mr. Davis for any purpose.
- (3) Engex, Inc. ("Engex") is an investment company registered under Section 8 of the Investment Company Act. Mr. Davis is the chairman of Engex, Inc. Filing of this statement shall not be deemed an admission by J. Morton Davis that he beneficially owns the securities attributed to Engex for any purpose. J. Morton Davis expressly disclaims beneficial ownership of all securities held by Engex for any purpose.
- (4) The Morton Foundation is a foundation whose trustees are Mrs. Davidowitz and her children. Mr. Davis expressly disclaims beneficial ownership of all securities held by The Morton Foundation for any purpose.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable
Item 8.	Identification and Classification of Members of the Group Not applicable
Item 9.	Notice of Dissolution of Group Not applicable
Item 10.	Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
	SIGNATURE
After reasonable	e inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February	10, 2012 By: /s/ Rosalind Davidowitz Name: Rosalind Davidowitz
	Page 5 of 5 Pages